Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmonary mucus: Pediatric perspective.

Duncan F Rogers1

  • 1Thoracic Medicine, National Heart and Lung Institute, Imperial College London, London, UK. duncan.rogers@imperial.ac.uk

Pediatric Pulmonology
|August 12, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Therapies to Inhibit Mucus Synthesis and Secretion in Airway Hypersecretory Diseases.

Pharmacology·2015
Same author

Therapeutic options for hydrating airway mucus in cystic fibrosis.

Pharmacology·2015
Same author

Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells.

Respiratory research·2012
Same author

New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways.

Journal of aerosol medicine and pulmonary drug delivery·2010
Same author

Phytoceuticals: the new 'physic garden' for asthma and chronic obstructive pulmonary disease.

Expert review of respiratory medicine·2010
Same author

Mucus hypersecretion in asthma: intracellular signalling pathways as targets for pharmacotherapy.

Current opinion in allergy and clinical immunology·2009

Childhood airway mucus hypersecretion shares similarities with adult conditions, suggesting similar treatments may be effective. Research is ongoing to identify specific pediatric therapeutic targets for mucus-related respiratory diseases.

Area of Science:

  • Pediatric Pulmonology
  • Respiratory Pathophysiology
  • Pharmacology

Background:

  • Airway mucus hypersecretion is common in childhood asthma and bronchitis.
  • Limited data exists on pediatric mucus pathophysiology compared to adults.
  • Similarities in conditions like goblet cell hyperplasia suggest shared mechanisms.

Purpose of the Study:

  • To explore the relevance of known adult therapeutic targets for childhood airway mucus hypersecretion.
  • To identify specific cellular targets for novel pediatric pharmacotherapies.
  • To address challenges in delivering treatments to children's airways.

Main Methods:

  • Review of existing evidence on adult and pediatric mucus hypersecretion.
  • Identification of potential therapeutic targets, including inflammatory cells and specific ion channels.

Related Experiment Videos

  • Consideration of drug delivery methods for pediatric populations.

    • Main Results:

    • Adult and childhood respiratory hypersecretory conditions show significant overlap.
    • Specific targets like epidermal growth factor receptor tyrosine kinase and calcium-activated chloride (CACL) channels are implicated.
    • Broader anti-inflammatory compounds may be beneficial, alongside highly specific targets like CACL1 channels.

    Conclusions:

    • Therapeutic strategies effective in adults may translate to pediatric respiratory diseases.
    • Targeting specific pathways, such as CACL1 channels, holds promise for treating childhood mucus hypersecretion.
    • Advances in inhaler technology are crucial for effective pediatric drug delivery.